| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8003681 | IRONWOOD PHARMS INC | 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester |
Aug, 2025
(1 year, 4 months from now) | |
| US8546436 | IRONWOOD PHARMS INC | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
Feb, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10183012 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(4 years from now) | |
| US8283369 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(4 years from now) | |
| US8546437 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Apr, 2029
(5 years from now) | |
| US8084483 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Aug, 2029
(5 years from now) | |
| US8357713 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Dec, 2029
(5 years from now) | |
| US9216179 | IRONWOOD PHARMS INC | Treatment of gout and hyperuricemia |
Aug, 2031
(7 years from now) | |
| US9956205 | IRONWOOD PHARMS INC | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
Dec, 2031
(7 years from now) | |
Duzallo is owned by Ironwood Pharms Inc.
Duzallo contains Allopurinol; Lesinurad.
Duzallo has a total of 9 drug patents out of which 0 drug patents have expired.
Duzallo was authorised for market use on 18 August, 2017.
Duzallo is available in tablet;oral dosage forms.
Duzallo can be used as treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone.
The generics of Duzallo are possible to be released after 29 February, 2032.
Drugs and Companies using ALLOPURINOL; LESINURAD ingredient
Market Authorisation Date: 18 August, 2017
Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone
Dosage: TABLET;ORAL
DUZALLO family patents
